Abstract 4779: Coxsackievirus A11 As a Novel Oncolytic Viral Therapy for Human Colorectal Cancer

Hisanobu Ogata,Beibei Wang,Shoei Miyamoto,Yuto Takishima,Miyako Sagara,Mutsunori Murahashi,Hideya Onishi,Kenzaburo Tani

DOI: https://doi.org/10.1158/1538-7445.sabcs18-4779

IF: 11.2

2019-01-01

Cancer Research

Abstract:Colorectal cancer (CRC) is a major cause of morbidity and mortality throughout the world. It is the third most common cancer worldwide and the fourth most common cause of death. FOLFOX is known as the effective chemotherapy for stage III and stage IV CRC. Oxaliplatin (L-OHP) is a third-generation platinum agent used among FOLFOX in CRC treatment. Patients with L-OHP-resistant CRC has a worse prognosis. Coxsackievirus is a virus that belongs to a family of nonenveloped, linear, positive-sense ssRNA viruses, Picornaviridae and the genus Enterovirus. Enteroviruses are among the most common and important human pathogens, and ordinarily its members are transmitted by the fecal-oral route. Coxsackieviruses share many characteristics with poliovirus. Coxsackieviruses are among the leading causes of aseptic meningitis. Recently, coxsackievirus A21, which is also called Cavatak, has already been reported to have the oncolytic activity. In this study, we tested whether coxsackievirus A11 (CVA11) has an oncolytic activity or not in CRC. Through our first screening assay, we found that CVA11 displayed the potent oncolytic activities in 4 of 5 various human CRC cell lines including two L-OHP-resistant CRC cells. Mechanistically, the CVA11-mediated cytotoxicity was significantly impaired when PI3K or Wnt inhibitor was added to the CVA11 infection. CVA11 had little effect on the L-OHP-resistant CRC. The pretreatment with L-OHP in L-OHP-resistant CRC cells displayed enhanced oncolytic activity of CVA11 in L-OHP-resistant CRC cells, whereas either L-OHP or CVA11 treatment alone caused slight oncolytic activity. These results suggest that L-OHP pretreatment could sensitize the susceptibility of CRC cells to CVA11 infection. Furthermore, our results of in vivo mouse study showed that intratumoral CVA11 administrations with pretreatment of L-OHP significantly suppressed the outgrowth of L-OHP-resistant xenografts. This combination therapy was more effective than the treatment with only CVA11. Altogether, our findings showed that the combination therapy with L-OHP and CVA11 displayed a remarkable oncolytic activity against L-OHP-resistant human CRC both in vitro and in vivo. Our study also provides the therapeutic potential for L-OHP-resistant CRC by Coxsackieviruse.Note: This abstract was not presented at the meeting.Citation Format: Hisanobu Ogata, Beibei Wang, Shoei Miyamoto, Yuto Takishima, Miyako Sagara, Mutsunori Murahashi, Hideya Onishi, Kenzaburo Tani. Coxsackievirus A11 as a novel oncolytic viral therapy for human colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4779.